Implementing buprenorphine in addiction treatment

Payer and provider perspectives in Ohio

Todd Molfenter, Carol Sherbeck, Mark Zehner, Andy Quanbeck, Dennis McCarty, Jee Seon Kim, Sandy Starr

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Background: Buprenorphine is under-utilized in treating opioid addiction. Payers and providers both have substantial influence over the adoption and use of this medication to enhance recovery. Their views could provide insights into the barriers and facilitators in buprenorphine adoption. Methods: We conducted individual interviews with 18 Ohio county Alcohol, Drug Addiction, and Mental Health Services (ADAMHS) Boards (payers) and 36 addiction treatment centers (providers) to examine barriers and facilitators to buprenorphine use. Transcripts were reviewed, coded, and qualitatively analyzed. First, we examined reasons that county boards supported buprenorphine use. A second analysis compared county boards and addiction treatment providers on perceived barriers and facilitators to buprenorphine use. The final analysis compared county boards with low and high use of buprenorphine to determine how facilitators and barriers differed between those settings. Results: County boards (payers) promoted buprenorphine use to improve clinical care, reduce opioid overdose deaths, and prepare providers for participation in integrated models of health care delivery with primary care clinics and hospitals. Providers and payers shared many of the same perceptions of facilitators and barriers to buprenorphine use. Common facilitators identified were knowledge of buprenorphine benefits, funds allocated to purchase buprenorphine, and support from the criminal justice system. Common barriers were negative attitudes toward use of agonist pharmacotherapy, payment environment, and physician prescribing capacity. County boards with low buprenorphine use rates cited negative attitudes toward use of agonist medication as a primary barrier. County boards with high rates of buprenorphine use dedicated funds to purchase buprenorphine in spite of concerns about limited physician prescribing capacity. Conclusions: This qualitative analysis found that attitudes toward use of medication and medication funding environment play important roles in an organization's decision to begin buprenorphine use and that physician availability influences an organization's ability to expand buprenorphine use over time.

Original languageEnglish (US)
Article number13
JournalSubstance Abuse: Treatment, Prevention, and Policy
Volume10
Issue number1
DOIs
StatePublished - Mar 28 2015

Fingerprint

Buprenorphine
Therapeutics
Financial Management
Physicians
Opioid Analgesics
Integrated Delivery of Health Care
Organizations
Criminal Law
Aptitude
Mental Health Services

Keywords

  • Buprenorphine
  • Medication-assisted treatment
  • Opioid addiction
  • Payer perspectives
  • Qualitative research

ASJC Scopus subject areas

  • Health Policy
  • Psychiatry and Mental health

Cite this

Implementing buprenorphine in addiction treatment : Payer and provider perspectives in Ohio. / Molfenter, Todd; Sherbeck, Carol; Zehner, Mark; Quanbeck, Andy; McCarty, Dennis; Kim, Jee Seon; Starr, Sandy.

In: Substance Abuse: Treatment, Prevention, and Policy, Vol. 10, No. 1, 13, 28.03.2015.

Research output: Contribution to journalArticle

Molfenter, Todd ; Sherbeck, Carol ; Zehner, Mark ; Quanbeck, Andy ; McCarty, Dennis ; Kim, Jee Seon ; Starr, Sandy. / Implementing buprenorphine in addiction treatment : Payer and provider perspectives in Ohio. In: Substance Abuse: Treatment, Prevention, and Policy. 2015 ; Vol. 10, No. 1.
@article{9383fdd998294cea95f38cafaaf5c1f4,
title = "Implementing buprenorphine in addiction treatment: Payer and provider perspectives in Ohio",
abstract = "Background: Buprenorphine is under-utilized in treating opioid addiction. Payers and providers both have substantial influence over the adoption and use of this medication to enhance recovery. Their views could provide insights into the barriers and facilitators in buprenorphine adoption. Methods: We conducted individual interviews with 18 Ohio county Alcohol, Drug Addiction, and Mental Health Services (ADAMHS) Boards (payers) and 36 addiction treatment centers (providers) to examine barriers and facilitators to buprenorphine use. Transcripts were reviewed, coded, and qualitatively analyzed. First, we examined reasons that county boards supported buprenorphine use. A second analysis compared county boards and addiction treatment providers on perceived barriers and facilitators to buprenorphine use. The final analysis compared county boards with low and high use of buprenorphine to determine how facilitators and barriers differed between those settings. Results: County boards (payers) promoted buprenorphine use to improve clinical care, reduce opioid overdose deaths, and prepare providers for participation in integrated models of health care delivery with primary care clinics and hospitals. Providers and payers shared many of the same perceptions of facilitators and barriers to buprenorphine use. Common facilitators identified were knowledge of buprenorphine benefits, funds allocated to purchase buprenorphine, and support from the criminal justice system. Common barriers were negative attitudes toward use of agonist pharmacotherapy, payment environment, and physician prescribing capacity. County boards with low buprenorphine use rates cited negative attitudes toward use of agonist medication as a primary barrier. County boards with high rates of buprenorphine use dedicated funds to purchase buprenorphine in spite of concerns about limited physician prescribing capacity. Conclusions: This qualitative analysis found that attitudes toward use of medication and medication funding environment play important roles in an organization's decision to begin buprenorphine use and that physician availability influences an organization's ability to expand buprenorphine use over time.",
keywords = "Buprenorphine, Medication-assisted treatment, Opioid addiction, Payer perspectives, Qualitative research",
author = "Todd Molfenter and Carol Sherbeck and Mark Zehner and Andy Quanbeck and Dennis McCarty and Kim, {Jee Seon} and Sandy Starr",
year = "2015",
month = "3",
day = "28",
doi = "10.1186/s13011-015-0009-2",
language = "English (US)",
volume = "10",
journal = "Substance Abuse: Treatment, Prevention, and Policy",
issn = "1747-597X",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - Implementing buprenorphine in addiction treatment

T2 - Payer and provider perspectives in Ohio

AU - Molfenter, Todd

AU - Sherbeck, Carol

AU - Zehner, Mark

AU - Quanbeck, Andy

AU - McCarty, Dennis

AU - Kim, Jee Seon

AU - Starr, Sandy

PY - 2015/3/28

Y1 - 2015/3/28

N2 - Background: Buprenorphine is under-utilized in treating opioid addiction. Payers and providers both have substantial influence over the adoption and use of this medication to enhance recovery. Their views could provide insights into the barriers and facilitators in buprenorphine adoption. Methods: We conducted individual interviews with 18 Ohio county Alcohol, Drug Addiction, and Mental Health Services (ADAMHS) Boards (payers) and 36 addiction treatment centers (providers) to examine barriers and facilitators to buprenorphine use. Transcripts were reviewed, coded, and qualitatively analyzed. First, we examined reasons that county boards supported buprenorphine use. A second analysis compared county boards and addiction treatment providers on perceived barriers and facilitators to buprenorphine use. The final analysis compared county boards with low and high use of buprenorphine to determine how facilitators and barriers differed between those settings. Results: County boards (payers) promoted buprenorphine use to improve clinical care, reduce opioid overdose deaths, and prepare providers for participation in integrated models of health care delivery with primary care clinics and hospitals. Providers and payers shared many of the same perceptions of facilitators and barriers to buprenorphine use. Common facilitators identified were knowledge of buprenorphine benefits, funds allocated to purchase buprenorphine, and support from the criminal justice system. Common barriers were negative attitudes toward use of agonist pharmacotherapy, payment environment, and physician prescribing capacity. County boards with low buprenorphine use rates cited negative attitudes toward use of agonist medication as a primary barrier. County boards with high rates of buprenorphine use dedicated funds to purchase buprenorphine in spite of concerns about limited physician prescribing capacity. Conclusions: This qualitative analysis found that attitudes toward use of medication and medication funding environment play important roles in an organization's decision to begin buprenorphine use and that physician availability influences an organization's ability to expand buprenorphine use over time.

AB - Background: Buprenorphine is under-utilized in treating opioid addiction. Payers and providers both have substantial influence over the adoption and use of this medication to enhance recovery. Their views could provide insights into the barriers and facilitators in buprenorphine adoption. Methods: We conducted individual interviews with 18 Ohio county Alcohol, Drug Addiction, and Mental Health Services (ADAMHS) Boards (payers) and 36 addiction treatment centers (providers) to examine barriers and facilitators to buprenorphine use. Transcripts were reviewed, coded, and qualitatively analyzed. First, we examined reasons that county boards supported buprenorphine use. A second analysis compared county boards and addiction treatment providers on perceived barriers and facilitators to buprenorphine use. The final analysis compared county boards with low and high use of buprenorphine to determine how facilitators and barriers differed between those settings. Results: County boards (payers) promoted buprenorphine use to improve clinical care, reduce opioid overdose deaths, and prepare providers for participation in integrated models of health care delivery with primary care clinics and hospitals. Providers and payers shared many of the same perceptions of facilitators and barriers to buprenorphine use. Common facilitators identified were knowledge of buprenorphine benefits, funds allocated to purchase buprenorphine, and support from the criminal justice system. Common barriers were negative attitudes toward use of agonist pharmacotherapy, payment environment, and physician prescribing capacity. County boards with low buprenorphine use rates cited negative attitudes toward use of agonist medication as a primary barrier. County boards with high rates of buprenorphine use dedicated funds to purchase buprenorphine in spite of concerns about limited physician prescribing capacity. Conclusions: This qualitative analysis found that attitudes toward use of medication and medication funding environment play important roles in an organization's decision to begin buprenorphine use and that physician availability influences an organization's ability to expand buprenorphine use over time.

KW - Buprenorphine

KW - Medication-assisted treatment

KW - Opioid addiction

KW - Payer perspectives

KW - Qualitative research

UR - http://www.scopus.com/inward/record.url?scp=84927509679&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84927509679&partnerID=8YFLogxK

U2 - 10.1186/s13011-015-0009-2

DO - 10.1186/s13011-015-0009-2

M3 - Article

VL - 10

JO - Substance Abuse: Treatment, Prevention, and Policy

JF - Substance Abuse: Treatment, Prevention, and Policy

SN - 1747-597X

IS - 1

M1 - 13

ER -